Stratos Wealth Partners LTD. Purchases New Position in Alexion Pharmaceuticals, Inc. (ALXN)

Stratos Wealth Partners LTD. purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,957 shares of the biopharmaceutical company’s stock, valued at approximately $415,000.

Other hedge funds also recently modified their holdings of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in Alexion Pharmaceuticals by 2.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 52,471 shares of the biopharmaceutical company’s stock worth $7,361,000 after purchasing an additional 1,039 shares during the last quarter. Comerica Bank increased its holdings in shares of Alexion Pharmaceuticals by 0.9% during the third quarter. Comerica Bank now owns 59,224 shares of the biopharmaceutical company’s stock worth $7,569,000 after buying an additional 503 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Alexion Pharmaceuticals by 1,758.1% during the third quarter. Teacher Retirement System of Texas now owns 105,742 shares of the biopharmaceutical company’s stock worth $14,835,000 after buying an additional 100,051 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Alexion Pharmaceuticals by 793.1% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 77,226 shares of the biopharmaceutical company’s stock worth $10,834,000 after buying an additional 68,579 shares in the last quarter. Finally, Toronto Dominion Bank increased its holdings in shares of Alexion Pharmaceuticals by 11.4% during the third quarter. Toronto Dominion Bank now owns 84,717 shares of the biopharmaceutical company’s stock worth $11,883,000 after buying an additional 8,646 shares in the last quarter. Institutional investors and hedge funds own 94.16% of the company’s stock.

In related news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,330 shares of company stock worth $774,851. 4.35% of the stock is owned by insiders.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up $2.79 during mid-day trading on Monday, hitting $111.75. 2,473,221 shares of the stock were exchanged, compared to its average volume of 2,288,616. The company has a market cap of $24,970.00, a PE ratio of 22.28, a PEG ratio of 1.19 and a beta of 1.18. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

ALXN has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. Royal Bank Of Canada upped their price target on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Finally, Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a report on Tuesday, October 24th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $155.06.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/04/stratos-wealth-partners-ltd-takes-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply